Therapeutic combinations

Details for Australian Patent Application No. 2005216710 (hide)

Owner Pfizer Inc.

Inventors Hammond, Jennifer Lou; Patick, Amy Karen

Agent Spruson & Ferguson

Pub. Number AU-A-2005216710

PCT Pub. Number WO2005/082362

Priority 60/540,749 30.01.04 US; 60/615,000 01.10.04 US

Filing date 17 January 2005

Wipo publication date 9 September 2005

International Classifications

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

A61K 31/41 (2006.01) - having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole

Event Publications

7 September 2006 PCT application entered the National Phase

  PCT publication WO2005/082362 Priority application(s): WO2005/082362

18 June 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005216712-Compositions comprising HIV protease inhibitor and cytochrome P450 enzyme activity inhibitor

2005216709-Antimicrobial preservatives to achieve multi-dose formulation using betacyclodextrins for liquid dosage forms